The names of its members (Taï Forest ebolaviruses) are to be capitalized, are not italicized, and used without articles.

TAFV is a Select Agent, World Health Organization Risk Group 4 Pathogen (requiring Biosafety Level 4-equivalent containment), National Institutes of Health/National Institute of Allergy and Infectious Diseases Category A Priority Pathogen, Centers for Disease Control and Prevention Category A Bioterrorism Agent, and listed as a Biological Agent for Export Control by the Australia Group.

Other names circulating in the literature were the correct Côte d'Ivoire Ebola virus and Côte d'Ivoire ebolavirus, and the jargon terms Ivory Coast Ebola virus and Ivory Coast ebolavirus.

EVD due to TAFV infection cannot be differentiated from EVD caused by other ebolaviruses by clinical observation alone, which is why the clinical presentation and pathology of infections by all ebolaviruses is presented together on a separate page (see Ebola virus disease).

TAFV made its first and thus far only known appearance in 1994 during a viral hemorrhagic fever epizootic among western chimpanzees (Pan troglodytes verus) in Taï National Park, Côte d'Ivoire.

As more dead western chimpanzees were discovered, many tested positive for infection with an ebolavirus distinct from those already known.

She developed symptoms similar to those of dengue fever approximately a week after the necropsy, and was transported to Switzerland for treatment.